Driving therapeutic innovation forward Corporate Presentation September 2025 Forward-Looking Statements This presentation contains "forward-looking statements," including statements regarding expectations, beliefs, intentions or strategies for the future. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, the potential success of our license agreements and joint venture, the commercial potential of motixafortide and GLIX1, expectations with re ...

Accessibility StatementSkip Navigation - GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks in cancer cells only - - FDAÂ IND clearance received for Phase 1/2a study, expected to initiate in Q1 2026 - -Â Glioblastoma market opportunity estimated to be in excess of $3.8 billion annually across the US and EU5 by 2030 - -Â BioLineRx affirms its cash runway into the first half of 2027 - Urgent Unmet Need and Significant Commercial Opportunity in Glioblastoma GBM is the most common a ...